Analysis · Regulation · November 2026

When will retatrutide be approved? The FDA timeline and the court case

The trials are finished and the filing is set for early 2027. The open question is whether the FDA reviews it as a biologic or as a drug.

A massive iron gate standing half open in fog, a single amber lamp lit above it, the path beyond it empty.

When will retatrutide be approved? Not before late 2027 on the FDA's own review clock. Eli Lilly has not filed it yet: the company said on 5 August 2026 that it plans to submit retatrutide to the FDA in the first quarter of 2027. As of 14 November 2026, retatrutide is not approved anywhere.

NOIs retatrutide FDA approved?Not as of 14 Nov 2026. Lilly has not filed yet. It plans to submit in the first quarter of 2027 (Lilly, 5 Aug 2026).
LATE 2027Earliest realistic decisionOur arithmetic from FDA review goals: about 8 months after filing with priority review, about 12 with standard.
OPENBiologic or drug?Lilly is appealing the FDA ruling that retatrutide is not a protein. Seventh Circuit argued 24 Sep 2026, no ruling found.
Sources: Lilly results of 5 August 2026; FDA PDUFA performance goals; Lilly v. Kennedy, No. 26-1301 (7th Cir.).

The argument of this piece is that the science behind retatrutide is no longer the slow part of the story. Lilly has announced three positive phase 3 obesity trials and a head-to-head win over Ozempic, and on 5 August it called the clinical package complete for obesity, obstructive sleep apnea and knee osteoarthritis pain. What remains open is a legal question that most timeline pages skip: whether the FDA must treat retatrutide as a biologic or as an ordinary drug. Lilly has been fighting the agency over that since 2024, and a federal appeals court heard the case on 24 September 2026. That fight shapes the filing, and it shapes how many years Lilly keeps the market to itself.

Nothing below is medical advice, and this page does not tell anyone whether to take, wait for or switch to any medicine. Doses appear only as the names of trial arms, the way Lilly reports them. Every date and figure comes from a source read on 14 November 2026 and linked at the foot of the page. The trial results are topline company announcements, not peer-reviewed papers, and the decision dates below are our arithmetic from published FDA goals, labelled as such each time.

When will retatrutide be approved by the FDA?

Retatrutide has no FDA approval date because Lilly has not yet submitted an application, and the FDA review clock only starts at submission. Lilly's second-quarter results release of 5 August 2026 states that the clinical data package is complete to support global registrations, with plans to submit a Biologics License Application to the FDA in the first quarter of 2027. The July 2026 announcement of the TRIUMPH-2 and TRIUMPH-3 results adds the reason for the wait: Lilly is still completing the chemistry, manufacturing and controls package that an application needs. The third-quarter release of 29 October 2026 reports new trial data and does not change that guidance. So the honest answer to "when" starts with a filing between January and March 2027.

From that filing, the FDA's published performance goals for fiscal years 2023 to 2027 set the pace. For a new molecular entity or an original biologics application, the FDA aims to act on 90 percent of standard applications within ten months of the 60-day filing date, about twelve months after submission, and on priority applications within six months of that date, about eight months after submission. Applied to a first-quarter 2027 filing, priority review points to roughly September to November 2027 and standard review to roughly January to March 2028. Those windows are our own arithmetic. Lilly has not said which review it expects, and we found no public priority designation for retatrutide.

Could the FDA approve retatrutide faster?

The FDA has a faster lane, and Lilly has used it before. Under the Commissioner's National Priority Voucher pilot, the agency's target is a decision within two months. On 1 April 2026 the FDA approved Lilly's oral GLP-1 orforglipron, sold as Foundayo, 50 days after filing and 294 days before its scheduled goal date, and called it the fastest approval of a new molecular entity since 2002. A voucher for retatrutide would pull a decision into the spring or summer of 2027. We found no announcement of one, from Lilly or from the FDA, and a reader should treat any page promising a 2027 launch date as speculation until one appears. The more likely path, on what is public today, is an ordinary review that ends between late 2027 and early 2028.

The trials answered whether retatrutide works. A court and a forty-amino-acid rule will decide how long Lilly keeps it to itself.

Why is Lilly fighting the FDA over whether retatrutide is a biologic?

Lilly is fighting the FDA because the classification of retatrutide decides how long the drug is protected from copies. Under federal law, a "protein" is a biological product, and FDA regulations define a protein as an alpha amino acid polymer greater than 40 amino acids in size. Lilly says retatrutide has 41 amino acids. On 18 March 2024 the FDA denied Lilly's request to designate it as a biologic, reasoning that only 40 of those 41 are alpha amino acids, according to Lilly's appeal brief. The stakes are commercial and large. An eligible reference biologic can receive 12 years of exclusivity before a biosimilar is approved; a new chemical drug approved through a new drug application typically receives five. BioSpace reported that the gap could be worth tens of billions of dollars to Lilly.

The courts have split the question. In an amended order of 3 October 2025, the US District Court for the Southern District of Indiana sided with the FDA that retatrutide is not a protein under the regulation, but held that the agency's finding that retatrutide is not even "analogous" to a protein was arbitrary and capricious. The court vacated that part of the decision and sent it back to the FDA, noting that the agency could lawfully reach the same conclusion. Final judgment was entered on 16 December 2025, and Lilly noticed its appeal to the Seventh Circuit on 12 February 2026. The appeal, No. 26-1301, was argued on 24 September 2026. We found no ruling and no published FDA decision on remand as of 14 November 2026.

Does the court case delay the retatrutide filing?

The court case does not stop Lilly from filing in early 2027, but it decides what kind of application the FDA treats it as. BioSpace reported that on its 5 August earnings call Lilly said it will pursue a BLA, and that chief executive David Ricks said the company believes retatrutide is a biologic both by amino acid count and as a product analogous to a protein. The same report says that if the FDA rejects a BLA, the drug could be delayed. That is the real risk to the timeline, and it is a legal risk rather than a scientific one. If the Seventh Circuit rules for Lilly before the filing, the path is clean. If it rules for the FDA, or does not rule in time, Lilly has to decide whether to file as a drug and accept five years of exclusivity, or keep pressing. Lilly has not said publicly which it would choose.

What did the retatrutide phase 3 trials show?

Retatrutide's phase 3 results are large, and they hold across populations. Retatrutide acts on three hormone receptors, GIP, GLP-1 and glucagon, where tirzepatide acts on two. In TRIUMPH-1, announced on 21 May 2026, 2,339 adults with obesity or overweight and without diabetes were randomised to three doses or placebo for 80 weeks. Average weight loss on the 12 mg arm was 28.3%, against 2.2% on placebo, counting participants while on treatment; counting everyone randomised, it was 25.0% against 3.9%. Those figures follow the phase 2 trial published in the New England Journal of Medicine in 2023, where the 12 mg group lost 24.2% at 48 weeks against 2.1% on placebo. TRIUMPH-2 and TRIUMPH-3 extended the result to diabetes and heart disease.

Trial (announced)Who and how longCompared withAverage weight loss, top dose
TRIUMPH-1 (21 May 2026)2,339 adults without diabetes, 80 weeksPlacebo28.3% vs 2.2%
TRIUMPH-2 (23 Jul 2026)1,152 adults with type 2 diabetes, 80 weeksPlacebo20.8% vs 4.0%
TRIUMPH-3 (23 Jul 2026)1,949 adults with BMI 35 or more and heart disease, 80 weeksPlacebo22.6% vs 3.2%
TRANSCEND-T2D-2 (28 Oct 2026)1,298 adults with type 2 diabetes, 80 weeks, open labelOzempic 2 mg20.9% vs 9.4%

Sources: Lilly news releases of the dates shown. Efficacy estimand, which counts participants while on treatment; top dose is the 12 mg arm. Topline results, not yet peer reviewed.

The tolerability record of retatrutide is where the caution belongs. In TRIUMPH-1, nausea was reported by 42.4% on the 12 mg arm against 14.8% on placebo, and 11.3% stopped treatment because of adverse events, against 4.9% on placebo. Dysesthesia, an abnormal or unpleasant skin sensation, appeared in 12.5% on 12 mg against 0.9% on placebo; Lilly says such events were generally mild to moderate and mostly resolved during treatment. In TRIUMPH-3, the heart-disease trial, the pre-specified five-part cardiovascular composite gave a hazard ratio of 0.82 with a confidence interval from 0.55 to 1.22, which does not show benefit or harm. A dedicated outcomes trial is what that question needs.

Can you get retatrutide before approval?

Retatrutide cannot be legally prescribed, sold or compounded in the United States before approval, outside a clinical trial or Lilly's own early-access route. The FDA's page on unapproved GLP-1 drugs states that "Retatrutide and cagrilintide cannot be used in compounding under federal law", because they are not components of approved drugs and have not been found safe and effective for any condition. The agency also says it has warned companies selling retatrutide falsely labelled "for research purposes" or "not for human consumption". AJMC reported on 5 August 2026 that Lilly had confirmed a narrow early-access route for a defined group of patients with refractory obesity, with criteria that differed between reports. Reason reported that on 12 August Lilly announced six lawsuits against sellers of research-use retatrutide. Our peptide and GLP-1 tracker and the guide to whether research peptides are safe cover that market.

Is the biologic fight a distraction from approval?

The strongest objection to this piece is that the court case is about money, not patients, and that the FDA will judge retatrutide on safety and efficacy whatever box it sits in. On the approval itself, the objection holds. Both pathways demand the same evidence that the drug is safe and effective, and the trial package Lilly describes is large: three placebo-controlled obesity trials of 80 weeks, a head-to-head diabetes trial, and data for sleep apnea and knee osteoarthritis pain. Nothing in the classification dispute questions those results. A reader who only wants to know whether retatrutide will be approved can reasonably expect a yes, on present evidence.

The objection is incomplete on timing and on what follows approval. The classification decides which application the FDA accepts, and BioSpace's report that a rejected BLA could delay the drug is a timing risk with no scientific cause. It also decides whether a lower-priced copy can arrive after five years or only after twelve, which matters for what patients and insurers pay through the 2030s. That is why we put the court case in the headline. The peptide reclassification fight showed that regulatory categories, not molecules, often decide who can sell what.

So when will retatrutide be available, in short?

Retatrutide is not approved and not yet filed. Lilly plans to submit in the first quarter of 2027, and on the FDA's published review goals a decision lands around late 2027 with priority review or early 2028 with standard review, by our arithmetic. A national priority voucher could bring that forward to mid-2027, and none has been announced. In trials, the 12 mg arm produced 28.3% average weight loss at 80 weeks, with more stomach side effects, more dropouts and a skin-sensation signal. The Seventh Circuit's ruling on whether retatrutide is a biologic is the event to watch next. We will update this page when Lilly files, when the court rules, and when the FDA sets a date.

Sources

  1. Eli Lilly and Company, second-quarter 2026 results (Form 8-K exhibit), 5 August 2026: clinical package complete, BLA submission planned for the first quarter of 2027. www.sec.gov
  2. Eli Lilly and Company, third-quarter 2026 results (Form 8-K exhibit), 29 October 2026. www.sec.gov
  3. Eli Lilly and Company, Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1), news release, 21 May 2026. www.biospace.com
  4. Eli Lilly and Company, retatrutide successful in two additional Phase 3 obesity trials (TRIUMPH-2 and TRIUMPH-3), news release, 23 July 2026. www.biospace.com
  5. Eli Lilly and Company, retatrutide versus Ozempic 2 mg in type 2 diabetes (TRANSCEND-T2D-2), news release, 28 October 2026. www.biospace.com
  6. Jastreboff AM et al., Triple-Hormone-Receptor Agonist Retatrutide for Obesity, a Phase 2 Trial, N Engl J Med 2023;389:514-526. pubmed.ncbi.nlm.nih.gov
  7. US District Court, Southern District of Indiana, Eli Lilly and Company v. Kennedy et al., No. 1:24-cv-01503, amended order on cross-motions for summary judgment, 3 October 2025. storage.courtlistener.com
  8. Eli Lilly and Company, Brief of Appellant, US Court of Appeals for the Seventh Circuit, No. 26-1301, filed 1 April 2026. storage.courtlistener.com
  9. BioSpace, Lilly, FDA retatrutide biologic dispute comes to a head as submission nears, August 2026. www.biospace.com
  10. MedPath (from BioPharm International and AJMC reports), Lilly's retatrutide classification fight heads to Seventh Circuit as BLA filing looms, 2 October 2026. trial.medpath.com
  11. Reason, Can a new weight loss treatment escape the legal and regulatory thicket?, 10 September 2026. reason.com
  12. FDA, PDUFA reauthorization performance goals and procedures, fiscal years 2023 through 2027. www.fda.gov
  13. FDA, FDA approves first new molecular entity under National Priority Voucher program, press announcement, 1 April 2026. www.fda.gov
  14. FDA, FDA's concerns with unapproved GLP-1 drugs used for weight loss, page read on 14 November 2026. www.fda.gov
  15. AJMC, Lilly expands retatrutide access amid doctor pushback, 5 August 2026. www.ajmc.com
Cite this pageOzemback. "When will retatrutide be approved? The FDA timeline and the court case." updated 14 November 2026. https://ozemback.com/blog/when-will-retatrutide-be-approved/

Frequently asked questions

Is retatrutide FDA approved?

No. As of 14 November 2026 retatrutide is not approved by the FDA or any other regulator, and Lilly has not yet submitted it. Lilly said on 5 August 2026 that it plans to submit a Biologics License Application in the first quarter of 2027.

When will retatrutide be available?

No date exists. Counting from a first-quarter 2027 filing, the FDA review goals put a decision around late 2027 with priority review and around early 2028 with standard review. That is our arithmetic, not a Lilly or FDA date, and launch can follow approval by weeks or months.

How much weight did people lose on retatrutide?

In TRIUMPH-1, announced by Lilly on 21 May 2026, average weight loss at 80 weeks was 28.3% on the 12 mg arm and 2.2% on placebo in 2,339 adults without diabetes, using the efficacy estimand. Counting everyone randomised, it was 25.0% against 3.9%.

Why is Lilly suing the FDA over retatrutide?

Lilly wants retatrutide classified as a biological product. On 18 March 2024 the FDA said it is not a protein because only 40 of its 41 amino acids are alpha amino acids. A biologic can receive 12 years of exclusivity, against 5 for a new chemical drug.

Can you get retatrutide now?

Only inside a clinical trial or Lilly's narrow early-access route, which Lilly confirmed on 3 August 2026 for a defined group of patients. The FDA states that retatrutide cannot be used in compounding under federal law and has warned sellers marketing it as a research chemical.

What are the side effects of retatrutide?

In TRIUMPH-1 the most common were gastrointestinal: nausea in 28.6% to 42.4% of retatrutide arms against 14.8% on placebo. Dysesthesia, an abnormal skin sensation, was reported in 5.1% to 12.5% against 0.9%. Lilly says those events were mostly mild to moderate.

Is retatrutide better than Ozempic?

In TRANSCEND-T2D-2, an open-label trial in 1,298 adults with type 2 diabetes announced on 28 October 2026, retatrutide 12 mg produced 20.9% weight loss at 80 weeks against 9.4% for Ozempic 2 mg, and an A1C fall of 2.2 points against 1.8.

Access note

The medications discussed here are prescription-only in the United States. They are legally dispensed through licensed clinicians and pharmacies, and through the telehealth platforms that hold direct supply agreements with Novo Nordisk and Eli Lilly. Ozemback is not a provider, takes no part in any clinical decision, and is not paid by any of them.

Your own numbers

Metabolic baseline

HbA1c · Fasting glucose · Fasting insulin · Lipid panel

The four numbers most often referenced in the trial literature covered on this site.

Consumer-initiated lab testing does not require a prescription in most US states. Ozemback does not interpret results, does not provide medical advice, and has no access to any reader's data. The link above is an affiliate link: if you buy a panel through it we receive a commission at no additional cost to you. We are paid for the referral, never for the result. Discuss any result with a licensed clinician.

One thoughtful letter per month.

If this essay was the kind of writing you have been missing, the monthly letter is more of it. First Sunday of every month. Free, never advice.

Subscribe to the letter
Editorial analysis, not medical advice Ozemback is an independent magazine. This essay is journalism and editorial opinion for informational purposes only and is not medical advice. The magazine does not recommend, endorse, or discourage any medication, dose, protocol, or course of treatment, and has no involvement in any clinical decision. Where we link to licensed providers, those links are clearly marked and some are affiliate links; a commission does not change what we publish. Always consult a qualified, licensed healthcare professional for any medical question or decision. See full Legal & Disclaimer.
Further reading
Ozemback is independent journalism. Nothing on this site is medical advice. Nothing replaces a licensed clinician. Read the disclaimer